Samuel Tremblay^1,#,*, Seyed Sajjad Tabei^2,#, Shima Tayebi³, Benjamin H. Hinrichs⁴, Alon Lazarovich¹, Jason Koehler³, Wei-Wen Hsu⁵, Sadhna Verma³, Abhinav Sidana¹

Canadian Journal of Urology, Vol.33, No.4, pp. 799-810, 2026, DOI:10.32604/cju.2026.075779 - 21 August 2026

Abstract Background: Focal therapy (FT) is an emerging treatment modality for localized prostate cancer. However, limited data are available regarding the patterns of oncologic failure post-FT. This study aims to characterize the features of oncologic failure and salvage strategies following FT. Methods: Patients presenting with pathologic failure (PF) after receiving FT (cryotherapy, High-intensity focused ultrasound, or irreversible electroporation) for intermediate-risk prostate cancer were selected from a prospective registry between 2018 and 2023. All patients underwent protocol-based follow-up, including PSA testing, multiparametric MRI, and mandatory biopsy. The primary outcome was PF, defined as biopsy-confirmed Grade Group ≥2… More >

Ramya Narasimhan¹, Kikuye Sugiyama^2,*, Joanna Wang³, Ricardo Munarriz³, Carmen Sarita-Reyes¹

Canadian Journal of Urology, Vol.33, No.4, pp. 1007-1017, 2026, DOI:10.32604/cju.2026.072310 - 21 August 2026

Abstract Background: The incidence rate of prostate adenocarcinoma in the United States was 112 per 100,000 in 2019. Men aged 65 to 74 years had a higher incidence rate (638 per 100,000), and 70% of the cases were detected locally (confined to the primary site) per the United States Cancer Statistics. While rare, prostate adenocarcinoma metastasis to the penis has variable presentation and potentially atypical histology that may require immunohistochemical, biomarker, and genetic analysis for confident diagnosis. Case Description: We present a 56-year-old patient with advanced prostate cancer post-chemoradiation and androgen deprivation therapy with an uncommon site… More >

Carla Simone Moreira Freitas^1,2,*, Fabiana Rocha-Silva², Thaís Almeida Marques-Silva², Ana Carolina Ribeiro de Oliveira¹, Sérgio Gomes da Silva^1,3,4, Fabrizio dos Santos Cardoso^1,5, Aleida Nazareth Soares²

Canadian Journal of Urology, Vol.33, No.4, pp. 827-839, 2026, DOI:10.32604/cju.2026.069559 - 21 August 2026

Abstract Background: Androgen deprivation therapy (ADT) is widely employed in the management of advanced prostate cancer, with luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide and goserelin being common options. However, pharmacological and metabolic differences between these agents may affect the efficacy of hormonal suppression and adverse event profiles. This study compared the effects of leuprolide (22.5 and 45 mg) and goserelin (10.8 mg) on prostate-specific antigen (PSA) and testosterone reduction, as well as their metabolic and cardiovascular impacts and the influence of genetic variants on therapeutic response. Methods: A prospective, randomized, controlled study was conducted… More >

Ernest A. Morton^*, Reza Lahiji, Elizabeth Chu, William Luke, Vivian I. Anyaeche, Dattatraya Patil, Akanksha Mehta, Shreyas S. Joshi, Taylor A. Goodstein, Valentina Grajales, Mohammad Hajiha

Canadian Journal of Urology, Vol.33, No.3, pp. 545-553, 2026, DOI:10.32604/cju.2026.073853 - 29 June 2026

Abstract Objectives: Prostate cancer (PCa) progression is influenced by a myriad of germline and/or somatic variants estimated to occur in 4.6%–11.8% of patients. Identified pathogenic variants may carry implications for treatment selection and prognosis. Despite the importance of genetic testing, referrals to counselling remain underutilized by urologists. This study aimed to understand referral patterns, testing uptake, and genetic results among men with PCa at a single large academic center. Methods: Records from 2010 to 2022 at Emory University were reviewed to identify men undergoing prostate biopsy and subsequent genetic counselling (CPT 96040). Referrals were confirmed as… More >

James T. Kearns^*, Cecilia Chang, Chi Wang, Christopher Ward, Henry M. Dunnenberger, Kristian Novakovic, Alexander P. Glaser, Brian T. Helfand

Canadian Journal of Urology, Vol.33, No.3, pp. 555-562, 2026, DOI:10.32604/cju.2025.073852 - 29 June 2026

Abstract Background: Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are common in aging men and are often concomitant. The purpose of the study was to evaluate whether Aquablation in men with BPH and early-stage PCa resulted in improvements in lower urinary tract symptoms (LUTS) and urinary quality of life (QoL) similar to men with only BPH. Furthermore, we explored active surveillance (AS) cancer outcomes in men undergoing Aquablation compared with a control AS population. Methods: Two prospective IRB (institutional review board)-approved databases were used to investigate outcomes in men with GG1 PCa on AS and… More >

Erdem Öztürk, Tuncel Uzel, Mustafa Işikdoğan^*, İsa Dağli, Nurullah Hamİdİ, Halil Başar

Canadian Journal of Urology, Vol.33, No.3, pp. 699-707, 2026, DOI:10.32604/cju.2025.071101 - 29 June 2026

Abstract Background: The European Association of Urology (EAU) recommends transperineal biopsy (TPBx) due to its lower infection risk and higher diagnostic rate for anterior zone tumors. This study aims to assess the learning curve of TPBx using the Perino-Flex^® angle-adjustable needle guide under local anesthesia. Methods: A retrospective observational analysis was conducted from November 2023 to March 2024, involving 100 patients who underwent TPBx with coaxial technique under local anesthesia. Data collected included patient demographics, procedure and room times, pain levels, anxiety scores, and complications. The study focused on comparing procedure times, pain scores, and complication rates… More >

Yangyang Zhang^1,2,3,#, Ilyar Mamtili^4,#, Yonghao Chen⁵, Guangjie Ji^1,2,3,*, Chaozhao Liang^1,2,3,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.079316 - 16 June 2026

Abstract Background: Prostate cancer (PCa) responds poorly to immunotherapy. We investigated the myeloid checkpoint TIM3 (HAVCR2) to define its lineage localization and regulatory logic in the PCa microenvironment. Methods: We integrated stage-resolved public single-cell RNA-seq datasets spanning primary PCa, metastatic hormone-sensitive PCa, and castration-resistant PCa. Myeloid compartments were analyzed via differential expression, regulon inference, and ligand–receptor modeling. Clinical relevance was evaluated in the Cancer Genome Atlas prostate adenocarcinoma (TCGA-PRAD) cohort and independent cohorts using a myeloid TIM3 signature. Mechanistic validation was achieved through PR domain zinc finger protein 1 (PRDM1) chromatin immunoprecipitation followed by Chromatin Immunoprecipitation (ChIP)–qPCR… More >

Yuan Guo^1,#, Hui Wang^2,#, Xiaoyu Zhao³, Xiao Feng³, Xingjian Cai⁴, Wei Li^3,*, Xiaohui Luo^4,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.078850 - 16 June 2026

Abstract Backgrounds: Early B-cell factor 1 (EBF1), originally identified as a critical transcription factor modulating the development and differentiation of B lymphocytes, has recently attracted significant interest owing to its diverse functional characteristics and regulatory mechanisms in solid tumors. Although current evidence suggests a potential connection between EBF1 and oncogenic developments, its exact role in the progression of prostate cancer (PCa) is unclear. This study sought to investigate its biological roles and regulatory mechanisms in human PCa. Methods: Bioinformatic analyses were performed utilizing Tumor Immune Estimation Resource (TIMER) 2.0, Gene Expression Profiling Interactive Analysis (GEPIA), and Gene… More >

Ashuai Du^1,#, Dianbin Guo^2,#, Dongbo Yuan^3,#, Kai Li⁴, Yuanyuan Luo⁴, Songsong Tan³, Xuchao Dai⁴, Bo Yu⁵, Wanxiang You⁶, Junjie Zhao⁷, Bo Yan³, Kehua Jiang^3,*, Xiaofei Fan^2,*, Jianguo Zhu^3,*,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.076716 - 22 April 2026

Abstract Background: Bisphenol A (BPA) is a widely used industrial chemical and endocrine-disrupting compound, and accumulating evidence suggests that it may contribute to prostate cancer progression; however, the underlying molecular mechanisms remain incompletely elucidated. This study aimed to elucidate the molecular targets and signaling pathways underlying BPA-induced prostate cancer progression. Methods: In this study, an integrated strategy combining network toxicology, molecular docking, and molecular dynamics simulations was employed to identify potential BPA-related targets and signaling pathways involved in prostate cancer. Candidate targets were retrieved from public databases, followed by protein-protein interaction network analysis to screen key… More >

Leonard G. Gomella

Canadian Journal of Urology, Vol.33, No.2, pp. 233-234, 2026, DOI:10.32604/cju.2026.083134 - 20 April 2026

Abstract This article has no abstract. More >